Finally, PD-1 antagonists such as nivolumab and CSFR1 inhibitors such as pexidartinib are relatively new to the field of bone cancer pain but show promising results in preclinical models that warrant further investigation. The gene discussed is PDCD1; the disease is bone neoplasm.